文献速递临床试验与 GCP流行病学与生物统计

低剂量利伐沙班对晚期肾病患者心血管事件的影响:TRACK随机临床试验

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

TRACK试验在90个中心纳入1458例高危心血管风险的晚期CKD(4/5期或透析)患者,随机接受利伐沙班2.5mg每日两次或安慰剂。试验因无效提前终止。

要点

  • 低剂量利伐沙班未降低晚期CKD患者主要心血管复合结局风险。
  • 利伐沙班组大出血发生率显著高于安慰剂组。
  • 该人群常规使用低剂量利伐沙班进行心血管预防缺乏获益证据。

核心结论

  • 在心血管高危的晚期CKD患者中,低剂量利伐沙班未降低复合心血管结局风险。
  • 低剂量利伐沙班组大出血发生率显著高于安慰剂组。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在12个国家90个中心开展。
  • 纳入1458例CKD 4期或5期及透析依赖的成人患者,随机1:1接受利伐沙班2.5mg每日两次或安慰剂。
  • 入组时间为2021年1月至2025年7月,因无效于2025年8月7日提前终止,最终随访至2025年10月30日。

主要发现

  • 中位随访1.7年,主要复合心血管结局在利伐沙班组发生164例(22.6%),安慰剂组151例(20.7%)。

关键数值与推荐

  • 主要复合结局包括心血管死亡、非致死性心肌梗死、卒中或外周动脉疾病事件。
  • 主要安全结局为大出血。

临床怎么用

  • 对于心血管高危的晚期CKD患者,低剂量利伐沙班不应用于常规心血管事件预防。
  • 临床决策时需权衡出血风险,该人群使用利伐沙班大出血风险显著增加。

局限性

  • 试验因无效提前终止,实际随访时间可能短于原计划。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Approximately 10% to 15% of patients with advanced chronic kidney disease (CKD) experience a fatal or nonfatal cardiovascular event annually. The effects of antithrombotic therapies on cardiovascular events in patients with advanced CKD are unknown. OBJECTIVE: To determine whether low-dose rivaroxaban reduces rates of adverse cardiovascular events compared with placebo in patients with advanced CKD. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted at 90 centers in 12 countries. Eligible participants were adults with CKD stage 4 or 5 and patients with dialysis-dependent kidney failure. Participants had a history of either coronary artery disease; nonhemorrhagic, nonlacunar stroke; peripheral artery disease; diabetes; or were 65 years or older. Enrollment occurred between January 2021 and July 2025. The trial was stopped early on August 7, 2025, for lack of efficacy. Final follow-up occurred on October 30, 2025. Statistical analyses were conducted in February and March 2026. INTERVENTIONS: Patients were randomized 1:1 to receive rivaroxaban 2.5 mg twice daily or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or a peripheral artery disease event. The primary safety outcome was major bleeding. RESULTS: Of 1458 randomized patients (mean [SD] age, 63.2 [11.6] years, 432 [29.6%] female), 1360 (93.3%) completed follow-up. During a median follow-up of 1.7 years, the primary outcome occurred in 164 patients (22.6%) in the low-dose rivaroxaban group and 151 (20.7%) in the placebo group (13.0 vs 11.8 events per 100 person-years; hazard ratio, 1.09 [95% CI, 0.87-1.36]; P = .46). Major bleeding occurred in 64 patients (8.8%) receiving low-dose rivaroxaban and 44 (6.0%) receiving placebo (5.1 vs 3.4 events per 100 person-years; hazard ratio, 1.51 [95% CI, 1.02-2.22]; P = .04). CONCLUSIONS AND RELEVANCE: In patients with advanced CKD at high cardiovascular risk, low-dose rivaroxaban did not reduce the risk of a composite cardiovascular outcome. Major bleeding rates were significantly higher in the low-dose rivaroxaban group compared with the placebo group. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03969953.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Badve SV, Perkovic V, Jha V, et al. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. JAMA. 2026. PMID: 42240165. doi:10.1001/jama.2026.9379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。